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Abstract
Background: Injection drug use remains a primary driver of HIV and HCV-related harms globally. However, there is
a gap in efforts to prevent individuals from transitioning into injecting. People who inject drugs (PWID) play a key
role in the transition of others into injecting, and while behavioral interventions have been developed to address
this phenomenon, socio-structural approaches remain unexplored. To that end, we hypothesize that certain
interventions designed to reduce injecting-related risk behaviors may also reduce the risk that PWID expose
and introduce others into injecting. Identifying the preventive potential of existing interventions will inform
broader efforts to prevent injecting and related harms.
Methods: The Preventing Injecting by Modifying Existing Responses (PRIMER) study is a multi-country mixed
methods study with an aim to investigate whether specific interventions (e.g., opioid substitution therapy, supervised
injection facilities, stable housing, incarceration environments) and related factors (e.g., public injecting and gender)
influence the likelihood that PWID initiate others into injecting. This study will (1) investigate the PWID participation in
injection initiation; (2) identify factors influencing the risk that PWID expose others to or facilitate injection initiation; (3)
describe drug scene roles that increase the risk of PWID facilitating injection initiation; and (4) evaluate the impact of
structural, social, or biomedical interventions on the risk that PWID facilitate injection initiation. It does so by pooling
observational data from cohort studies of PWID in six cities: Vancouver, Canada; San Diego, USA; Tijuana, Mexico; Paris,
Marseille, and Bordeaux, France.
Results: Team members are conducting a prospective, multi-site study of PWID (n = 3050) in North America and
France that includes quantitative and qualitative data collection through four separate cohort studies of PWID (San
Diego, STAHR II; Tijuana, El Cuete IV; Vancouver, V-DUS; Bordeaux, Marseille, Paris and Strasbourg, COSINUS).
Conclusions: PRIMER is the largest study of injection initiation to date and the first to investigate structural approaches
to preventing injection drug use initiation. Findings have the potential to inform the development and scale up of new
and existing interventions to prevent transitions into injecting.
Trial registration: Preventing Injecting by Modifying Existing Responses (PRIMER), NIDA DP2-DA040256-01.
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site study
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Background
Injection drug use remains a primary source of HIV- and
hepatitis C (HCV)-related harms [1], with a recent esti-
mate suggesting that 15.9 million people inject drugs glo-
bally. Among this population, three million (19 %) are
believed to be HIV-positive [1], while ten million people
who inject drugs (PWID) are estimated to be HCV-
positive [2], with prevalence among PWID populations
believed to exceed 60 % in 37 countries [2]. The median
age of injection initiation globally is 19, indicating that
more than half of PWID initiate injecting as adolescents
or young adults [3]. Of concern, data also suggest that the
window of opportunity to prevent blood-borne virus
transmission among new injectors is limited, given that
the majority of incident HCV and hepatitis B virus cases
occur within 1 year of initiation [4], which may be due to
elevated incidence of risk behaviors such as syringe shar-
ing among recently initiated injectors [1]. The increased
addictive potential of injecting also creates challenges in
preventing risky drug-related behaviors [5]. As such,
injecting remains a primary driver of HIV and viral hepa-
titis epidemics worldwide. Recent increases in prescription
opioid misuse in North America may be contributing to a
heightened risk of injection initiation [6], given that the
use of prescription opioids such as oxycodone has been
shown to be associated with a heightened risk of initiating
injecting [7].
Studies to date suggest that the majority of injection ini-
tiation events are facilitated, either directly or indirectly,
by PWID [8–19]. For example, among a sample of street
youth who reported injecting drugs in Vancouver, Canada
(n = 369), almost three quarters reported being initiated
by other injectors [10]. Among a cohort of PWID in
Tijuana, Mexico (n = 1052), only 11 % reported initiat-
ing injection alone [20]. In France, among the PWID
enroled in a cross-sectional study in five cities (n = 1077;
Lille, Strasbourg, Paris, Bordeaux, and Marseille), 83 % of
participants reported having been initiated by another per-
son [21]. A qualitative study undertaken among a sample
of newly initiated PWID in New York City (n = 54) also
found that decisions to begin injecting were influenced by
previous exposure to injecting and that initiates actively
sought out PWID to assist with initiation [12]. Determin-
ing the local factors driving such trends is critical in devel-
oping adaptable and effective interventions to prevent
epidemics of injecting.
In particular, preventing injection initiation requires
an understanding of individual roles within drug scenes
that may place PWID at higher risk of initiating others.
For example, “hit doctors” (i.e., individuals paid with
money or drugs to inject others) may be asked for injec-
tion assistance by customers at the time they purchase
their drugs. Hit doctors are often present in and around
risky injecting environments such as shooting galleries
and public injecting venues [22] and may be sources of
injecting education [23], placing them at higher risk of
being approached for injection initiation assistance. Im-
portantly, the context of initiation may also differ based
on the gender of both initiates and initiators, with fe-
male initiates being more likely to be injected by older
male PWID, who are often intimate partners [24]. These
findings suggest that PWID facilitate transitions to
injecting in multiple ways: by exposing injection-naïve
drug users to injecting [10], by providing injecting edu-
cation [12], and by directly injecting initiates [15]. While
a minority of PWID report facilitating injection initiation
events, those who do may initiate numerous individuals.
Among a sample of Californian PWID (n = 605), for ex-
ample, 35 % (n = 214) reported never initiating others
into injecting, with a total of 3271 individuals initiated
into injecting [15]. Similarly, while only 17 % (n = 55) of
a sample of Australian PWID (n = 324) reported initiat-
ing others, they initiated 128 new injectors [16].
Reducing the exposure of injection-naïve drug users to
injecting practices is therefore likely to reduce their risk
of transitioning into injecting. Interestingly, data suggest
that neighborhoods with high levels of public injecting
are sites of increased population mixing between PWID
and non-injectors [14]. For example, non-injecting street
youth in Vancouver residing in the downtown eastside,
which is characterized by high rates of public injecting,
reported a cumulative incidence of initiation after 3 years
that was over twice that reported by non-injecting street
youth residing elsewhere in the city [14]. Evidence also
suggests that the deployment of intense policing of
street-level drug markets is likely to intensify risky injec-
tion practices [25] and may also increase the exposure of
non-injectors to PWID by dispersing drug markets
spatially [26] or by increasing the risk that PWID will
inject in public or semipublic venues, a phenomenon
that has been widely observed across a range of set-
tings [27–35]. The incarceration of PWID likely also
increases the risk that they may expose or initiate
non-injectors to injecting, given the potential for
population mixing in prison [17] (this is of particular
interest given recent moves towards de-incarceration
of PWID in California and Mexico [36]).
Although there is strong evidence that PWID play a
key role in the initiation of other individuals into injec-
tion drug use [13], there are few interventions that pre-
vent injection initiation by focusing on the role of PWID
in this practice [13]. To date, these have by and large
employed behavioral approaches that seek to directly
alter the individual-level decision-making of PWID at
risk of initiating others into injecting. There is therefore
a dearth of research and intervention development fo-
cused on modifying the social and structural factors that
in turn influence PWID to initiate others.
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We hypothesize that the interventions that reduce the
frequency of public injecting may have the secondary
benefit of preventing injection initiation by limiting the
exposure of non-injectors to injecting. For instance, opi-
oid substitution therapies (OST) including methadone
and buprenorphine maintenance therapy, supervised in-
jection facilities (SIF), and stable housing for PWID have
all been shown to reduce the risk of PWID injecting in
public venues [37]. If public injecting increases the ex-
posure of non-injectors to injecting, the provision of
such interventions may therefore reduce the risk that
PWID expose injection-naïve drug users to injecting,
thereby decreasing the latter’s risk of injection initiation.
Within settings characterized by population mixing be-
tween PWID and non-injectors, there is often a “code”
or ethic among established injectors discouraging the
initiation of others, but facilitating initiation may be dif-
ficult to avoid for PWID who may be offered money or
drugs to facilitate initiation events [9]; this may be par-
ticularly acute in the context of individuals with sub-
stance use disorders who lack resources to purchase
drugs or have inadequate access to addiction treatments
such as OST.
Given the gaps in knowledge regarding injection initi-
ation, as well as the lack of effective interventions focused
on this practice, a 5-year multi-country study has been de-
veloped to investigate structural, social, and biomedical
approaches to preventing injection initiation and to iden-
tify individual pathways and drug scene roles associated
with facilitating initiation. Herein, we describe the meth-
odology as well as the participant and site characteristics.
Methods
Preventing Injecting by Modifying Existing Responses:
PRIMER
The Preventing Injecting by Modifying Existing Re-
sponses (PRIMER) is a US National Institute on Drug
Abuse-funded study (DP2- DA040256-01; PI: Werb)
seeking to determine whether interventions effective in
reducing public injecting can reduce the initiation of
others into injecting and to then employ these findings
to develop a socio-structural interventional approach to
preventing injection drug use.
Conceptual framework
Rhodes’ risk environment framework allows for the in-
vestigation of the social and structural environment ex-
perienced by PWID and an identification of how this
may limit the capacity of PWID to avoid drug-related
harm [38, 39], including high risky injection practices
such as exposing injection-naïve drug users to injecting
behaviors [40]. The risk environment framework also al-
lows for an examination of how interactions between so-
cial, structural, physical, and political/economic influences
operating at micro, meso, and macro levels of an individ-
ual’s environment may shape their local drug scene and
behavior. This is particularly useful in considering the
intersection of individual-level behaviors—in this case, ex-
posing or initiating others into injecting—with a range of
social, structural, and economic factors operating at mul-
tiple levels. PRIMER will examine the interaction of
individual-level factors such as OST enrolment, housing
status, spatial proximity to non-injectors, income level,
and level of drug dependence; meso-level factors such as
the presence of shooting galleries, public injecting settings,
SIF implementation, OST programs, and drug use pat-
terns in local PWID populations; and macro-level factors
such as the type of drug policies and housing policies in
place, along with the availability of illicit drugs (Fig. 1).
This approach is consistent with interventional ap-
proaches that consider points of maximum effect and
the interaction of factors, at the structural level
(macro), environmental level (meso), and individual
level (micro) [41].
Fig. 1 Conceptual framework to investigate injection initiation events facilitated by established injectors
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Approach
The PRIMER study has four major aims across two
phases. Phase I consists of mixed methods data collec-
tion and analysis. Phase II consists of the evaluation of
an interventional approach to prevent injection initiation
informed by the findings of phase I. Aim 1 is to deter-
mine the prevalence and characteristics of PWID partici-
pation in injecting initiation across multiple study sites.
Aim 2 is to assess factors potentially influencing the risk
that PWID facilitate injecting initiation. Primary factors
of interest are as follows: enrolment in OST, SIF access,
stable housing, a history of incarceration, public injec-
tion, and gender. Aim 3 is to qualitatively investigate in-
dividual pathways and roles that increase the risk of
PWID facilitating injecting initiation. This involves ex-
ploring local social norms across study sites related to
injecting others among PWID through in-depth inter-
viewing. We will specifically investigate gender within
the context of injecting initiation events, with a focus on
intimate partnerships. We will also explore the role of
injecting environments (e.g., shooting galleries, jails/
prisons, SIF, public vs. private settings) and drug scene
roles (e.g., hit doctors, drug dealers, sex workers) that
may heighten the risk that PWID facilitate injecting ini-
tiation. Finally, participants’ own initiation events will be
explored to determine how they influence subsequent
decisions to initiate others. Finally, aim 4 (carried out in
phase II) is to test the impact of an existing structural or
biomedical intervention on the risk that PWID will facili-
tate injecting initiation. Based on the findings generated
through the exploration of aims 1–3, we will evaluate the
implementation and/or scale-up of an interventional ap-
proach addressing the factors that most greatly influence
the risk that PWID initiate others into injecting.
In phase I, quantitative and qualitative data on in-
volvement in injection initiation collected from PWID
aged 18 years and older in three longitudinal cohort
studies in North America and one longitudinal cohort
study in France are being pooled and analyzed. These
data are being used to determine the prevalence and
characteristics of PWID participation in injection initi-
ation across multiple study sites, to assess a range of fac-
tors at multiple levels that potentially influence the risk
that PWID facilitate injection initiation, and to investi-
gate individual pathways and roles that increase the risk
of PWID facilitating injection initiation. This consists of
both quantitative and qualitative data collection to ex-
plore local contexts and social norms related to PWID’s
initiation of others into injecting in each study site.
Study sites
While we hypothesize that structural, social, and bio-
medical interventions to reduce injection-driven HIV
and HCV transmission risk might also reduce the risk
that PWID facilitate injection initiation, we anticipate
that the impact of these interventions will be mediated
by unique local characteristics in different settings and
among discrete populations of PWID. PRIMER there-
fore includes longitudinal data from four cohort studies
of PWID aged 18 and older located in urban settings in
the USA (PI Dr. Richard Garfein, Study to Assess Hepatitis
C Risk (STAHR II); San Diego, CA; NIH R01-DA031074);
Tijuana, Mexico (PI Dr. Steffanie Strathdee, Proyecto El
Cuete IV (ECIV); Tijuana; NIH R37-DA019829); Vancouver,
Canada (PI Dr. Thomas Kerr, V-DUS; Vancouver; NIH R01-
DA011591); and France (PIs Pr. Marc Auriacombe and Drs.
Marie Jauffret-Roustide and Perrine Roux, COhorte pour
l’évaluation des facteurs Structurels et INdividuels de l’USage
de drogues (COSINUS); Bordeaux, Marseille, Paris, and
Strasbourg; INSERM/MILDECA C14-26).
Quantitative data collection
Identical questions on the involvement of PWID in in-
jection initiation were seeded into cohort survey instru-
ments in September 2014 and have been integrated into
broader data collection protocols. Questions solicit data
on participants’ experiences with initiating others into
injecting, the reasons for doing so, the relationship be-
tween initiates and initiators (including their gender),
and the self-perceived likelihood that participants would
initiate others in the future. These questions form the
basis of the project’s quantitative data collection and will
allow for investigations of the lifetime history and recent
experiences (i.e., past 6 months) of PWID’s facilitation of
injection initiation. Importantly, these cohort studies all
seek to investigate HIV risk behaviors among PWID res-
iding in urban centers, and their survey instruments
share important similarities that facilitate cross-site
comparisons. Additionally, the STAHR II and El Cuete
IV study instruments were intentionally designed for
cross-study comparisons [42]. Prior to data pooling, each
participant’s data is assigned a unique identifier (including
a site locator) to avoid duplication or misclassification.
Recruitment for all participant cohort studies is via
targeted sampling methods that include outreach activ-
ities, snowball sampling methods, and self-referral. Po-
tential participants are invited to participate in the
study, and in the case of STAHR II, El Cuete IV, and
VIDUS II, those individuals who consent are asked to
provide a specimen for rapid HIV testing (COSINUS
participants do not undergo serologic testing). Outreach
staff, including interviewers, frontline personnel, and
field staff, as well as nurses, are, in all cases, familiar
with local neighborhoods and the social structural con-
texts of injection drug use and have extensive experience
in recruiting and following up with participants from
local PWID networks. The field offices employed for
participant interviews and interactions are designed as
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low-threshold, easily accessible, and friendly environ-
ments, with staff trained to be courteous and respectful
of participants. In all studies, staff involved—and par-
ticularly research coordinators and outreach staff—have
extensive experience working with addicted and margin-
alized individuals. Study interviewers are trained in sur-
vey administration, techniques to ensure trust and
rapport with participants, and methods to ensure confi-
dentiality. All interviews take approximately 60–90 min
and are conducted in secure field offices and locales
PWID are known to frequent. All follow-up interviews
occur at 6-month intervals.
Statistical analytic plan
Our primary analytic approach employs generalized linear
mixed models (GLMM), which addresses problems of at-
trition, missing data, variable timing of subject visits, and
other unintended violations of design. Temporal correla-
tions between subject responses are assumed using an
autoregressive structure, with subject-specific variances
and correlations assumed to decline exponentially over
time. Importantly, this approach also allows for the inclu-
sion of study site as a nesting factor. To evaluate the im-
pact of socio-structural factors on the risk that PWID
facilitate injection initiation, GLMM models will be fitted
with reporting recent (i.e., past 6 months) injection initi-
ation facilitation as the outcome. This is defined using the
following survey item: “In the last 6 months, have you
helped anybody inject who had never injected before?”
(yes vs. no). The primary independent variables of interest
are defined as follows: recent (i.e., past 6 months) OST en-
rolment, recent attendance at a SIF (Vancouver only), re-
cent housing stability, recent incarceration, recent public
injecting, and gender. To investigate how local settings
impact risk, the effect of the independent variables of
interest on facilitating injection initiation is being evalu-
ated separately for each location. We anticipate a range of
confounders which may influence the association between
our outcome variable and independent variables of
interest. While these are likely to vary across sites, we
anticipate testing the impact of the following: intimate
partnerships, migration, stigma, HIV status, mental
health, health-care utilization, level of drug depend-
ence, income level, ethnicity, and attitudes regarding
social norms around injecting.
Qualitative data collection
In-depth qualitative interviews will be conducted among
participants from all cohort studies. Sampling is purpos-
ive and based on either reporting facilitated injection ini-
tiation in quantitative interviews or with reporting no
injection initiation but having a quantitative “profile”
(i.e., identical answers to a set of relevant cohort survey
items) consistent with other participants that report
facilitating injection initiation. This approach allows for
qualitative comparisons between individuals who do and
do not initiate others into injecting despite a profile that
suggests that they are at risk; this will facilitate the de-
velopment of targeted interventional approaches. We
will weight our sampling based on the experience with
the independent variables of interest. For example, to
ensure recruitment of hit doctors and drug dealers, we
will recruit participants who indicate in quantitative sur-
veys that they have initiated others into injecting and
have also undertaken these drug scene roles. We will
seek to recruit 25–35 participants from each cohort. In
qualitative interviews, we will specifically investigate
gendered dynamics within the context of injection initi-
ation events, with a focus on intimate partnerships. We
will also explore the role of injecting environments (e.g.,
shooting galleries, jails/prisons, SIF, public vs. private
settings) and drug scene roles (e.g., hit doctors, drug
dealers, sex workers) that may heighten the risk that
PWID facilitate injection initiation. Finally, we will ex-
plore the participants’ accounts of their own initiation
events to determine how these influence subsequent de-
cisions to initiate others.
Qualitative analysis
Grounded theory will be used as the overarching con-
ceptual approach to qualitative data collection and ana-
lysis [43, 44]. Grounded theory is founded on an
approach that assumes that one’s communication and
actions express a meaning that is both individually held
and shared socially [43]. As such, grounded theory al-
lows for the identification and delineation of core pro-
cesses or assumptions that underlie specific individual
actions or social interactions, with the ultimate aim of
identifying a coherent model for the individual and so-
cial actions observed. In the context of identifying indi-
vidual pathways toward injection initiation, as well as
the social relationships that may propel an individual to
begin injecting, grounded theory will be employed to
collect and analyze data in order to develop a model of
injection initiation grounded in social interaction.
Mixed methods analytic plan
A parallel mixed methods design is being employed,
which is followed by a meta-inference process wherein
results of the quantitative and qualitative analyses are
being synthesized [45]. This approach represents an
“ethno-epidemiological” research design, as it integrates
targeted qualitative research in relation to epidemio-
logical cohort studies, and greater understanding of the
lived experience of PWID can add a deeper social di-
mension to traditional quantitative measures regarding
specific outcomes (in this case, injection initiation), as
has been done previously [46–48]. Because effect sizes
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for each independent variable of interest will differ
across study sites, qualitative findings are being used to
determine which causal pathways, individual roles, or re-
lationships shape these differences. The meta-inference
process is iterative and, as data are collected and trian-
gulated, will refine our understanding of the factors driv-
ing PWID to facilitate initiation.
Phase II intervention development strategy
The type of intervention, or combination, to be tested in
phase II will be determined after the analysis of findings
from phase I. This tailored approach extends to the selec-
tion of the most appropriate setting for evaluation. As out-
lined above, important differences exist across study sites,
with interventions being scaled up or implemented during
the study period; the situation “on the ground” in each
study site, in combination with phase I findings, will
therefore determine which site is ultimately selected for
evaluation and whether an existing, modified, or novel
intervention is evaluated. While dependent on findings,
we have identified methodological approaches appropriate
for intervention testing. Community randomization, with
experimental and delayed onset control arms, may be ap-
propriate to test interventions such as subsidized OST or
SIF. Interrupted time-series analyses may also be suitable
to test widespread policy change (e.g., de-incarceration).
Discrete HIV epidemics are driven by local dynamics,
and we therefore anticipate that the findings generated in
phase I will likely demonstrate that a combination of
socio-structural factors heighten the risk that PWID facili-
tate injection initiation, and thereby contribute to a higher
population-level risk of HIV transmission. As above, rele-
vant potential factors vary greatly by study setting and
have implications for the impact and optimal combination
of interventions. For example, in Vancouver, a combin-
ation of OST and SIF access may reduce the risk that
PWID initiate others; in Tijuana, access to stable housing
and de-incarceration may be found to most greatly reduce
risk. In San Diego, with low OST enrolment and high
levels of homelessness, and a rapid move towards de-
incarceration [49], multiple potential interventional points
exist. In France, OST coverage is very high (70–80 %) (and
has been accompanied by a reduction in the overall inci-
dence of sharing behaviors and HIV and HCV transmis-
sion in local contexts [50, 51]); this provides an
opportunity to determine how scale up of OST may im-
pact injection initiation risk.
Study sites
Table 1 provides relevant study site and baseline partici-
pant characteristics for each cohort study included in
PRIMER. These data do not include COSINUS sample
data given that data collection for this cohort has not yet
started. We also present data from the VIDUS II cohort,
which is being transitioned into the V-DUS study in
2016 in order to integrate cohorts of PWID and street-
involved youth, some of whom are injection-naïve. The
estimated sample sizes for each cohort are as follows:
STAHR II, n = 575; Proyecto El Cuete, n = 750; V-DUS,
n = 1735; and COSINUS, n = 680. As such, the pooled
sample size for PRIMER will approach 3740 participants,
though we caution that missing data, loss to follow-up,
and incompatibility between variables in cohort ques-
tionnaires are likely to reduce this overall number. As
can be seen in Table 1, female participants comprise be-
tween 26 and 38 % of the cohort participants, and HIV
prevalence at baseline ranged from 0–10 % (note that
only HIV-seronegative PWID participants are eligible for
inclusion in VIDUS II, though V-DUS will not include
this restriction). Overall, the prevalence of lifetime his-
tory of accessing OST was highest in Vancouver (53 %)
and lowest in Tijuana (28 %). In Vancouver, 23 % of par-
ticipants also reported accessing OST in the past
6 months. We anticipate that reported OST access will
be higher among COSINUS participants given much
higher levels of OST scale up in France [52].
Ethics, consent, and permissions
The study was provided ethical approval by the Institu-
tional Review Board of the University of California, San
Table 1 Baseline cohort characteristics
Study Location Number Eligible age
range
Study period OST uptake SIF
present
Homeless in the
past 6 months (%)
Incarceration HIV+ in
sample (%)
Female
(%)
Proyecto El
Cuete IV
Tijuana, Mexico 750 18+ 2010–2020 28 % ever No 20 71 % ever 5 38
STAHR II San Diego, USA 575 18+ 2012–2016 23 % ever No 55 78 % ever 10 26
V-DUSa Vancouver, Canada 1735 18+ 1996–2020 53 % ever Yes 5 19 % ever 0d 31
COSINUSb Paris, Marseille,
Bordeaux, and
Strasbourg, France
680 18+ 2016–2018 – Yesc – – – –
aRefers to current VIDUS II sample (set to merge into V-DUS in 2016)
bData collection to begin in Fall 2016
cSIF likely to be implemented in Paris and Strasbourg in Fall 2016
dAll VIDUS II participants are HIV-negative at baseline
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Diego School of Medicine (UCSD IRB 150866). We have
also obtained consent to publish and report individual
participant data.
Results and discussion
Injection drug use remains one of the key drivers of HIV
and HCV epidemics worldwide. And yet, very few inter-
ventions have proven effective in preventing individuals
from initiating injection drug use. Although experts sup-
port efforts to reduce injecting exposure through
individual-level behavioral change among PWID [13],
structural approaches to reducing the risk that PWID
expose and initiate others into injecting have not yet
been adequately developed. While preliminary data
strongly suggest that PWID play a central role in facili-
tating injection initiation, a critical gap in programing to
address this practice remains.
PRIMER, which seeks to harness the preventive poten-
tial of existing structural, social, and biomedical HIV in-
terventions, is, to our knowledge, unique in addressing
this gap in public health programing. This is highly rele-
vant given the potential for increases in injection drug
use presented by the rising prevalence of prescription
opioid misuse in North America [6], the emergence and
expansion of epidemics of injecting in West and Sub-
Saharan Africa and Asia [53], and the potential impact
of widespread OST coverage on mitigating injection ini-
tiation risk. We also anticipate that the mixed methods
analytic approach we employ will further confirm gender
and drug market roles (e.g., hit doctors) as uniquely con-
tributing to the risk of injection initiation posed by
PWID [11, 12]; this may allow for the development of
gender-specific interventions to prevent injection initi-
ation. A peer-based intervention tailored to other spe-
cific subpopulations may be required to reduce the risk
that certain PWID initiate others; these might include
Break the Cycle or the “heroin sniffers” projects (both
behavioral interventions that seek to build resilience
among PWID to avoid initiating others) [13], which are
currently being studied in combination in a research trial
being carried out in New York City, USA, and Talinn,
Estonia [54]. Relatedly, the potential that hit doctors
may be more likely to initiate others might also require
adaptation of existing injection education interventions
[55]. These models generally involve peer educators who
disseminate information about safer injection practices
[56]; as such, they could be used to also disseminate
strategies to discourage injection initiation, as well as to
provide information to PWID on accessing existing in-
terventions such as OST and SIF.
With respect to the selection of study sites, the deci-
sion was based primarily on a recognition, as above, that
patterns of injection drug use initiation are driven by
unique local dynamics. We therefore sought to include
sites that represented diverse economic, legal, policy, and
cultural settings. We note that while these site characteris-
tics can be identified a priori, other important factors that
may influence patterns of injecting initiation—particularly
stigma, drug use trends, discrete social networks, and so-
cial norms around injecting—will be identified during the
study and will be used to inform intervention develop-
ment. Specifically, Vancouver has a large, densely located
PWID population, with a high but declining prevalence of
HIV [57]. In the mid-1990s, drug use patterns among
PWID shifted from heroin to cocaine injection, which was
undertaken with higher frequency, resulting in higher
rates of contaminated syringe sharing and a subsequent
increase in HIV incidence [58]. Subsequently, a range of
harm reduction and ancillary services were implemented
or scaled-up, such as OST and a limited number of SIFs
[57], including a peer-run unsanctioned SIF that allows
assisted injection [59]. The existing of a peer-run SIF may
allow for intervention among individuals such as hit doc-
tors who may more frequently engage in injection initi-
ation events [60].
San Diego is characterized by a PWID population esti-
mated most recently at approximately 20,000 (standard
deviation 12,000) [61] highly dispersed across the
county. PWID in San Diego report primarily injecting
with heroin and crystal methamphetamine [62]. HIV
prevalence among PWID is estimated at 4 % [42], and
access to services such as needle exchange and OST is
low. Importantly, California has had among the most
stringent criminal justice responses to drug use and pos-
session since 1994 and has experienced extreme prison
overcrowding [49]. However, the passage in November
2014 of Proposition 47, a statute that reclassifies non-
violent drug crimes from felonies to misdemeanors, will
result in the release of potentially 10,000 currently incar-
cerated individuals and is estimated to contribute to
40,000 fewer felony convictions annually [49]. This site
therefore presents an opportunity to assess the impact of
a large-scale structural intervention on injection initi-
ation risk, in a setting currently characterized by high in-
carceration rates.
Tijuana has a densely situated local PWID population
(estimated N = 10,000), located primarily within the
Zona Norte neighborhood (adjacent to the US-Mexico
border) [63], with a high level of population mixing be-
tween PWID and non-injectors as a result of deportation
from the USA [64, 65]. HIV prevalence is low (i.e., 4 %)
[42], and addiction treatment and harm reduction ser-
vices are under-resourced [66]. However, the passage of
a partial drug decriminalization law in 2009 has seen a
gradual shift towards increased addiction treatment
scale-up (including OST) in Tijuana [67]. Accordingly,
the number of OST clinics has increased slightly, while
shifting policing strategies are beginning to impact the
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rate of diversion of PWID towards addiction treatment
services [36]. The STAHR II and El Cuete IV study in-
struments were deliberately designed to be identical to
allow cross-border comparisons of PWID in these adja-
cent cities [42].
France (Bordeaux, Marseille, Paris, and Strasbourg) is
unique in having high levels of OST scale-up, with an es-
timated 180,000 individuals reporting OST access [50]
(in specific sites, estimates of OST access among PWID
exceed 70 %) [68, 69]. Further, despite delays, SIF are ex-
pected to be implemented in at least one study site (i.e.,
Paris) during the project period [70, 71], providing an
opportunity to investigate how a combination of high
OST coverage and SIF access may impact PWID risk of
facilitating initiation.
Strengths and limitations
The employment of existing NIDA-funded cohort study
mechanisms ensures that data are of high quality and
that sufficient statistical power for analyses is obtained.
The focus on multiple factors (i.e., OST enrolment, SIF
access, housing status, incarceration, public injecting,
and gender), in isolation and in combination, also allows
for a high degree of adaptation to local contexts. It also
provides a foundation for future modeling of the broader
impact of these interventions on injection drug use pre-
vention in a variety of settings.
This project, though, has limitations. First, it is likely
that participation in injection initiation may be underre-
ported by PWID given the stigma associated with this
behavior [12], which may result in threats to statistical
power or misclassification of data. However, the large es-
timated sample size (n = 3760) provides a large amount
of statistical power. Second, there may be discrepancies
in data collection across sites that may limit our analyses
(i.e., ECIV and STAHR II both employ computer-
assisted personal interviewing (CAPI), while V-DUS does
not (nor will COSINUS), which may result in misclassifi-
cation given that recall of risk behaviors may differ be-
tween cohort participants interviewed via CAPI and
those interviewed using other techniques) [72–74].
However, as noted, all study questionnaires are highly
comparable, and we are undertaking extensive qualita-
tive data collection as part of a mixed methods approach
to obtain a more contextualized and detailed under-
standing of the roles, social influences, and contexts that
shape PWID risk of facilitating injection initiation.
Third, while study samples may not be generalizable,
data from multiple settings allows for an understanding
of how socio-structural factors in combination impact
the risk of injection initiation and, ultimately, of HIV
transmission. Fourth, challenges with scale-up exist with
all interventions. However, team members have exten-
sive experience in implementing and evaluating cutting-
edge HIV interventions [75] and have also developed in-
stitutional and multi-sectoral partnerships to support
such activities in all study sites.
Conclusions
There is a critical gap in the global development and
scale-up of evidence-based responses to preventing injec-
tion initiation. Given the contribution of injecting to the
risk of transmission of HIV and other blood-borne dis-
eases, it is imperative that resources be allocated towards
identifying effective approaches to preventing injection
drug use, rather than focusing solely on injection-related
health harms. To ensure maximum effectiveness, any pre-
ventive approach must also be both adaptable to a range
of settings and easily integrated into the suite of current
public health programing designed to address the needs of
drug-using populations [76]. These are the collective goals
of PRIMER, and we anticipate that study findings will help
support the development and evaluation of a comprehen-
sive and scalable approach to reducing the incidence of
injection-related morbidity and mortality experienced in a
wide range of settings internationally [1, 77–79].
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